3SBio Inc.:企業の医薬品パイプラインレビュー(2014年)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC04796CDB)
◆英語タイトル:3SBio Inc. - Product Pipeline Review - 2014
◆発行会社/調査会社:Global Markets Direct
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[3SBio Inc.:企業の医薬品パイプラインレビュー(2014年)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

3SBio Inc. – Product Pipeline Review – 2014


Global Markets Direct’s, ‘3SBio Inc. – Product Pipeline Review – 2014’, provides an overview of the 3SBio Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of 3SBio Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of 3SBio Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of 3SBio Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the 3SBio Inc.’s pipeline products

Reasons to buy

- Evaluate 3SBio Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of 3SBio Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the 3SBio Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of 3SBio Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of 3SBio Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of 3SBio Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
3SBio Inc. Snapshot 5
3SBio Inc. Overview 5
Key Information 5
Key Facts 5
3SBio Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
3SBio Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
3SBio Inc. – Pipeline Products Glance 13
3SBio Inc. – Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
3SBio Inc. – Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
3SBio Inc. – Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
3SBio Inc. – Drug Profiles 17
voclosporin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Product Description 20
Mechanism of Action 20
R&D Progress 20
Uricase-PEG 20 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
APX-001 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AT-406 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DJ-5 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SSS-08 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
3SBio Inc. – Pipeline Analysis 29
3SBio Inc. – Pipeline Products by Target 29
3SBio Inc. – Pipeline Products by Route of Administration 31
3SBio Inc. – Pipeline Products by Molecule Type 32
3SBio Inc. – Pipeline Products by Mechanism of Action 33
3SBio Inc. – Recent Pipeline Updates 35
3SBio Inc. – Dormant Projects 40
3SBio Inc. – Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
NuLeusin 41
3SBio Inc. – Company Statement 42
3SBio Inc. – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
3SBio Inc., Key Information 5
3SBio Inc., Key Facts 5
3SBio Inc. - Pipeline by Indication, 2014 8
3SBio Inc. - Pipeline by Stage of Development, 2014 9
3SBio Inc. - Monotherapy Products in Pipeline, 2014 10
3SBio Inc. - Partnered Products in Pipeline, 2014 11
3SBio Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
3SBio Inc. - Phase III, 2014 13
3SBio Inc. - Phase I, 2014 14
3SBio Inc. - IND/CTA Filed, 2014 15
3SBio Inc. - Preclinical, 2014 16
3SBio Inc. - Pipeline by Target, 2014 30
3SBio Inc. - Pipeline by Route of Administration, 2014 31
3SBio Inc. - Pipeline by Molecule Type, 2014 32
3SBio Inc. - Pipeline Products by Mechanism of Action, 2014 34
3SBio Inc. - Recent Pipeline Updates, 2014 35
3SBio Inc. - Dormant Developmental Projects,2014 40
3SBio Inc. - Discontinued Pipeline Products, 2014 41
3SBio Inc., Other Locations 43
3SBio Inc., Subsidiaries 43

List of Figures
3SBio Inc. - Pipeline by Top 10 Indication, 2014 7
3SBio Inc. - Pipeline by Stage of Development, 2014 9
3SBio Inc. - Monotherapy Products in Pipeline, 2014 10
3SBio Inc. - Partnered Products in Pipeline, 2014 11
3SBio Inc. - Pipeline by Top 10 Target, 2014 29
3SBio Inc. - Pipeline by Top 10 Route of Administration, 2014 31
3SBio Inc. - Pipeline by Top 10 Molecule Type, 2014 32
3SBio Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 33

*** 免責事項 ***

※当市場調査資料(GMDHC04796CDB )"3SBio Inc.:企業の医薬品パイプラインレビュー(2014年)" (英文:3SBio Inc. - Product Pipeline Review - 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。